Goodwin is representing ARTBIO on the matter. AlphaGen Therapeutics (“AlphaGen”), a biopharmaceutical company, and ARTBIO, Inc., a clinical-stage radiopharmaceutical company developing a new class of targeted...
You must be a Standard 1 Year member to access this content.
Goodwin advised Myrobalan Therapeutics on the matter. Myrobalan Therapeutics has been granted $400,000 from the ALS Association to support the advancement of its colony-stimulating factor-1 receptor...
You must be a Standard 1 Year member to access this content.
Goodwin represented Base Therapeutics on the matter. Base Therapeutics announced the out-licensing of its proprietary base editing technology on a non-exclusive basis to a leading international biopharmaceutical...
You must be a Standard 1 Year member to access this content.
Goodwin represented Myrobalan Therapeutics on the matter. Myrobalan Therapeutics announced its $24 million Series A financing. The round was led by Co-win Ventures, with participation from...
You must be a Standard 1 Year member to access this content.
Goodwin advised Legend Capital on the deal. Legend Capital announced its multi-million Pre-A round investment in N1 Life. The invested funds will be used for further screening...
You must be a Standard 1 Year member to access this content.
Goodwin advised Moderna, Inc. on the deal. Moderna, Inc. (Nasdaq:MRNA) announced its strategic collaboration with Generation Bio Co. (Nasdaq:GBIO) to combine Moderna’s biological and technical expertise with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Legend Capital on the deal. Legend Capital announced its leading investment in Nuwacell Biotechnologies’ Series A financing round. Legend Capital is a private equity...
You must be a Standard 1 Year member to access this content.
Goodwin advised Triastek, Inc. on the deal. Triastek, Inc. announced its collaboration with Eli Lilly and Company to leverage the advantages of 3D printing technology to enable...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Palleon Pharmaceuticals on the deal. Palleon Pharmaceuticals announced its strategic collaboration agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize two bifunctional...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma, Inc. on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced its exclusive license agreement wit Bristol Myers Squibb to develop and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Eluminex Biosciences on the deal. Eluminex Biosciences (Suzhou) Limited (Eluminex) announced its acquisition of certain assets and the related global development and commercialization rights...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Qilu Pharmaceutical on the deal. Qilu Pharmaceutical, one of the leading pharmaceutical companies in China (“Qilu”), announced its exclusive licensing agreement and strategic partnership...
You must be a Standard 1 Year member to access this content.
